摘要
背景:β地中海贫血的表型严重程度受β-珠蛋白突变、α-地中海贫血的共遗传和与胎儿血红蛋白产生相关基因的多态性三种遗传修饰因子的高度调控。本研究旨在探讨HBF相关基因主要存在于HBB簇、BCL11A(B细胞CLL/淋巴瘤11A)和HBS1L-MYB(HBS 1样翻译型GTPase-MYB原癌基因、转录因子)对临床严重程度的影响。方法:对149例患者进行调查。采用多重PCR、Sanger测序和多重连接依赖探针扩增技术对HBA和HBB突变进行分析。此外,采用质谱和PCR-限制性片段长度多态性(PCRRFLP)对35种HBF多态性进行了基因分型。用SPSSVersion 22进行基因型-表型关联分析。结果:在研究人群中发现了21个HBB突变.HBB突变患者由于其他次级修饰物的存在,其表型严重程度不同。α-地中海贫血的共遗传(n=12)减轻了β-地中海贫血的疾病严重程度.3种多态性(HBS1LMYB,rs4895441[P=0.008,OR=0.38(0.18,0.78)],rS 9376092[P=0.030,OR=0.36(0.14,0.90)];嗅觉受体[OR51B2]rs6578605[P=0.018,OR=0.52(0.31,0.89)]与表型严重程度有关。对HBF单核苷酸多态性与HBF水平关系的二次分析表明,HBS1L-MYB中有三个表面意义显著的SNPs:rs 6934903、rs 9376095和rs 9494149。结论:本研究揭示了3种HBF多态性在改善β-地中海贫血患者病情严重程度中的重要作用,可作为临床管理的预测指标。
关键词: β-地中海贫血,HBF修饰物,疾病严重程度,基因型-表型关联,多态性,突变。
Current Molecular Medicine
Title:Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in β-Thalassemia Patients
Volume: 18 Issue: 5
关键词: β-地中海贫血,HBF修饰物,疾病严重程度,基因型-表型关联,多态性,突变。
摘要: Background: The phenotypic severity of β-thalassemia is highly modulated by three genetic modifiers: β-globin (HBB) mutations, co-inheritance of α-thalassemia and polymorphisms in the genes associated with fetal haemoglobin (HbF) production. This study was aimed to evaluate the effect of HbF related polymorphisms mainly in the HBB cluster, BCL11A (B-cell CLL/lymphoma 11A) and HBS1L-MYB (HBS1-like translational GTPase-MYB protooncogene, transcription factor) with regards to clinical severity.
Methods: A total of 149 patients were included in the study. HBA and HBB mutations were characterised using multiplex PCR, Sanger sequencing and multiplex ligationdependent probe amplification. In addition, 35 HbF polymorphisms were genotyped using mass spectrometry and PCR-restriction fragment length polymorphism (PCRRFLP). The genotype-phenotype association was analysed using SPSS version 22.
Results: Twenty-one HBB mutations were identified in the study population. Patients with HBB mutations had heterogeneous phenotypic severity due to the presence of other secondary modifiers. Co-inheritance of α-thalassemia (n = 12) alleviated disease severity of β-thalassemia. In addition, three polymorphisms (HBS1LMYB, rs4895441 [P = 0.008, odds ratio (OR) = 0.38 (0.18, 0.78)], rs9376092 [P = 0.030, OR = 0.36 (0.14, 0.90)]; and olfactory receptor [OR51B2] rs6578605 [P = 0.018, OR = 0.52 (0.31, 0.89)]) were associated with phenotypic severity. Secondary analysis of the association between single-nucleotide polymorphisms with HbF levels revealed three nominally significant SNPs: rs6934903, rs9376095 and rs9494149 in HBS1L-MYB.
Conclusion: This study revealed 3 types of HbF polymorphisms that play an important role in ameliorating disease severity of β-thalassemia patients which may be useful as a predictive marker in clinical management.
Export Options
About this article
Cite this article as:
Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in β-Thalassemia Patients, Current Molecular Medicine 2018; 18 (5) . https://dx.doi.org/10.2174/1566524018666181004121604
DOI https://dx.doi.org/10.2174/1566524018666181004121604 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Psoralen: A Biologically Important Coumarin with Emerging Applications
Mini-Reviews in Medicinal Chemistry Luteolin Stimulates Proliferation and Inhibits Late Differentiation of Primary Rat Calvarial Osteoblast Induced by High-dose Dexamethasone via Sema3A /NRP1/Pleixin A1
Current Pharmaceutical Biotechnology Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Current Drug Targets Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Regulation of T Cell Signaling and Function by Cbl-b
Current Immunology Reviews (Discontinued) The Use of Microarrays to Study Childhood Developmental Brain Disorders
Current Genomics Monoclonal Antibodies as Innovative Therapeutics
Current Pharmaceutical Biotechnology Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus
Current Pharmaceutical Design Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Opioid Free Anaesthesia and Cancer
Current Pharmaceutical Design Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
Current Cancer Drug Targets